Odds ratios for prevalent thrombotic/ischemic events in individuals with JAK2 V617F–positive non-MPNs and mutation-positive MPNs compared with nonmutated in 2 multiadjusted models with and without blood cell counts included
| . | Nonmutated . | JAK2 V617F <1% . | JAK2 V617F ≥1% . | MPN . | Model 1, odds ratio (95% CI)* . | P . | Model 2, odds ratio (95% CI)† . | P . | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Total | 19 313 | 507 | 92 | 16 | — | — | — | — | ||
| IHD, n (%) | 441 (2.3) | 16 (3.2) | 3 (3.3) | 0 | <1%: | .95 (0.54-1.7) | .9 | <1%: | 0.97 (0.55-1.7) | .9 |
| ≥1%: | .67 (0.19-2.4) | .5 | ≥1%: | 0.74 (0.21-2.7) | .6 | |||||
| MPN: | — | — | MPN: | — | — | |||||
| VTE, n (%) | 363 (1.9) | 8 (1.6) | 6 (6.5) | 2 (13) | <1%: | .71 (0.33-1.5) | .4 | <1%: | 0.71 (0.33-1.5) | .4 |
| ≥1%: | 2.8 (1.1-7.0) | .03 | ≥1%: | 3.0 (1.2-7.8) | .02 | |||||
| MPN: | 6.0 (1.3-28) | .02 | MPN: | 5.6 (1.1-28) | .04 | |||||
| ICVD, n (%) | 494 (2.6) | 17 (3.4) | 2 (2.2) | 3 (19) | <1%: | 1.1 (0.64-1.8) | .8 | <1%: | 1.0 (0.61-1.7) | .9 |
| ≥1%: | .57 (0.14-2.4) | .4 | ≥1%: | 0.44 (0.10-1.9) | .3 | |||||
| MPN: | 4.6 (1.2-18) | .03 | MPN: | 3.5 (0.89-14) | .07 | |||||
| . | Nonmutated . | JAK2 V617F <1% . | JAK2 V617F ≥1% . | MPN . | Model 1, odds ratio (95% CI)* . | P . | Model 2, odds ratio (95% CI)† . | P . | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Total | 19 313 | 507 | 92 | 16 | — | — | — | — | ||
| IHD, n (%) | 441 (2.3) | 16 (3.2) | 3 (3.3) | 0 | <1%: | .95 (0.54-1.7) | .9 | <1%: | 0.97 (0.55-1.7) | .9 |
| ≥1%: | .67 (0.19-2.4) | .5 | ≥1%: | 0.74 (0.21-2.7) | .6 | |||||
| MPN: | — | — | MPN: | — | — | |||||
| VTE, n (%) | 363 (1.9) | 8 (1.6) | 6 (6.5) | 2 (13) | <1%: | .71 (0.33-1.5) | .4 | <1%: | 0.71 (0.33-1.5) | .4 |
| ≥1%: | 2.8 (1.1-7.0) | .03 | ≥1%: | 3.0 (1.2-7.8) | .02 | |||||
| MPN: | 6.0 (1.3-28) | .02 | MPN: | 5.6 (1.1-28) | .04 | |||||
| ICVD, n (%) | 494 (2.6) | 17 (3.4) | 2 (2.2) | 3 (19) | <1%: | 1.1 (0.64-1.8) | .8 | <1%: | 1.0 (0.61-1.7) | .9 |
| ≥1%: | .57 (0.14-2.4) | .4 | ≥1%: | 0.44 (0.10-1.9) | .3 | |||||
| MPN: | 4.6 (1.2-18) | .03 | MPN: | 3.5 (0.89-14) | .07 | |||||
P values in bold are <.05.
ICVD, ischemic cerebrovascular disease; IHD, ischemic heart disease; JAK2 V617F <1%/≥1%, JAK2 V617F positives with allele burden <1% or ≥1%, respectively, without MPN; VTE, venous thromboembolism (deep vein thrombosis and/or pulmonary embolism).
Adjusted for age, sex, smoking, alcohol, C reactive protein, hemoglobin A1c, cholesterol, blood pressure, and body mass index.
Adjusted for age, sex, smoking, alcohol, C reactive protein, hemoglobin A1c, cholesterol, blood pressure, body mass index, hemoglobin, leukocytes, and thrombocytes.